Overview

Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19

Status:
Completed
Trial end date:
2021-10-07
Target enrollment:
Participant gender:
Summary
A phase 2, placebo-controlled study of the safety and efficacy of STI-5656 (Abivertinib Maleate) in subjects hospitalized due to COVID-19
Phase:
Phase 2
Details
Lead Sponsor:
Sorrento Therapeutics, Inc.
Treatments:
Abivertinib
Maleic acid